Granted Patent
B2
US 11,952,352 · App. 18/161,266 · Granted Apr 9, 2024
Ras inhibitors
Inventors:
Adrian L. Gill (Atherton, CA); James Cregg (Belmont, CA); Elena S. Koltun (Foster City, CA); Yang Liu (Foster City, CA)
Assignee:
Revolution Medicines, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims (7)
1. A compound of the following structure:
or a pharmaceutically acceptable salt thereof.
2. A compound of the following structure:
3. A pharmaceutical composition comprising a compound of the following structure:
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising a compound of the following structure:
and a pharmaceutically acceptable excipient.
Assignments (2)
SECURITY INTEREST
Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 6, 2023
From: KOLTUN, ELENA S.; CREGG, JAMES; GILL, ADRIAN L.; AGGEN, JAMES; BURNETT, G. LESLIE; PITZEN, JENNIFER; BUCKL, ANDREAS; KNOX, JOHN E.; LIU, YANG
To: REVOLUTION MEDICINES, INC.
Reel/Frame 062602/0231 →
Continuity (7)
Provisional Application
63043588
· Jun 24, 2020
Provisional Application
63011636
· Apr 17, 2020
Provisional Application
63000357
· Mar 26, 2020
Provisional Application
62951652
· Dec 20, 2019
Provisional Application
62930355
· Nov 4, 2019